Experimental therapies and clinical trials in bone sarcoma.
Sarcomas originating in the bone represent a challenge for physicians and patients. Because they constitute only 0.2% of all adult malignancies and 6% of pediatric malignancies, resources for studying this disease are often limited. Nonetheless, significant advancements have been made in the treatment of this disease, and there are ongoing efforts toward improvement. This article discusses recently completed and currently enrolling clinical trials for the 3 most common bone sarcomas: osteosarcoma, Ewing's sarcoma family tumors, and chondrosarcoma.
Chugh
Rashmi
R
Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan 48109-5843, USA. rashmim@med.umich.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors* / Q000378:metabolism; D001859:Bone Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D002813:Chondrosarcoma / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D012516:Osteosarcoma / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D012512:Sarcoma, Ewing / Q000378:metabolism / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor